Research programme: mRNA therapeutics - AstraZeneca/Moderna Therapeutics
Alternative Names: VEGF-A modified mRNA; VEGF-A modRNALatest Information Update: 28 Feb 2021
At a glance
- Originator AstraZeneca; Moderna Therapeutics
- Class Antineoplastics; Cardiovascular therapies; RNA
- Mechanism of Action Protein synthesis stimulants; Vascular endothelial growth factor A expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Metabolic disorders
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Intracardiac, Injection)
- 28 Feb 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 Feb 2021 No recent reports of development identified for research development in Metabolic-disorders in USA (Parenteral)